Renaissance Technologies LLC decreased its holdings in shares of Agile Therapeutics, Inc. (NASDAQ:AGRX) by 47.0% in the 1st quarter, according to its most recent 13F filing with the SEC. The fund owned 33,900 shares of the specialty pharmaceutical company’s stock after selling 30,100 shares during the period. Renaissance Technologies LLC’s holdings in Agile Therapeutics were worth $109,000 at the end of the most recent reporting period.
Separately, Royce & Associates LP raised its position in shares of Agile Therapeutics by 206.1% during the 1st quarter. Royce & Associates LP now owns 987,582 shares of the specialty pharmaceutical company’s stock valued at $3,165,000 after acquiring an additional 665,000 shares during the last quarter. Institutional investors own 67.59% of the company’s stock.
Agile Therapeutics, Inc. (NASDAQ:AGRX) opened at 4.01 on Friday. The stock’s 50 day moving average is $3.49 and its 200-day moving average is $3.49. The firm’s market capitalization is $115.51 million. Agile Therapeutics, Inc. has a 1-year low of $1.82 and a 1-year high of $7.95.
Agile Therapeutics (NASDAQ:AGRX) last announced its quarterly earnings results on Friday, July 28th. The specialty pharmaceutical company reported ($0.26) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.28) by $0.02. During the same quarter in the previous year, the firm earned ($0.29) EPS. Analysts forecast that Agile Therapeutics, Inc. will post ($1.01) EPS for the current year.
In other Agile Therapeutics news, Chairman Alfred Altomari purchased 10,000 shares of the company’s stock in a transaction that occurred on Friday, August 25th. The shares were bought at an average cost of $3.34 per share, for a total transaction of $33,400.00. Following the purchase, the chairman now owns 161,587 shares of the company’s stock, valued at approximately $539,700.58. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 3.50% of the company’s stock.
WARNING: This piece of content was first posted by BBNS and is owned by of BBNS. If you are reading this piece of content on another site, it was illegally stolen and reposted in violation of U.S. & international copyright & trademark legislation. The legal version of this piece of content can be viewed at https://baseballnewssource.com/markets/agile-therapeutics-inc-agrx-stake-lowered-by-renaissance-technologies-llc/1604218.html.
Several analysts have commented on the stock. Cantor Fitzgerald reiterated a “buy” rating and set a $8.00 target price on shares of Agile Therapeutics in a research report on Thursday. Noble Financial restated a “buy” rating on shares of Agile Therapeutics in a research report on Sunday, July 30th. ValuEngine cut shares of Agile Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Friday, September 1st. Janney Montgomery Scott restated a “buy” rating and issued a $13.00 price objective (down previously from $15.00) on shares of Agile Therapeutics in a research report on Thursday, August 24th. Finally, Royal Bank Of Canada upped their price objective on shares of Agile Therapeutics from $8.00 to $10.00 and gave the company an “outperform” rating in a research report on Thursday, September 14th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and six have given a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of $8.92.
Agile Therapeutics Company Profile
Agile Therapeutics, Inc is a women’s health specialty pharmaceutical company. The Company is focused in the development and commercialization of prescription contraceptive products. The Company has developed a transdermal patch technology, called Skinfusion. The Company’s lead product candidate is Twirla, also known as AG200-15, is a combined hormonal contraceptive (CHC) patch.
Receive News & Ratings for Agile Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agile Therapeutics Inc. and related companies with our FREE daily email newsletter.